MA37961A1 - Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation - Google Patents

Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Info

Publication number
MA37961A1
MA37961A1 MA37961A MA37961A MA37961A1 MA 37961 A1 MA37961 A1 MA 37961A1 MA 37961 A MA37961 A MA 37961A MA 37961 A MA37961 A MA 37961A MA 37961 A1 MA37961 A1 MA 37961A1
Authority
MA
Morocco
Prior art keywords
her2 antibodies
new therapeutic
therapeutic treatments
low fucosylation
fucosylation anti
Prior art date
Application number
MA37961A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Steffen Goletz
Antje Danielczyk
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of MA37961A1 publication Critical patent/MA37961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA37961A 2012-12-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation MA37961A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197768 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (en) 2012-07-18 2013-07-18 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
MA37961A1 true MA37961A1 (fr) 2016-06-30

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37961A MA37961A1 (fr) 2012-12-18 2013-07-18 Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation

Country Status (16)

Country Link
US (1) US20150166664A1 (enExample)
EP (1) EP2874658A1 (enExample)
JP (1) JP2015528802A (enExample)
KR (1) KR20150036710A (enExample)
CN (1) CN104394887A (enExample)
AU (1) AU2013291964B2 (enExample)
BR (1) BR112014032169A2 (enExample)
CA (1) CA2875486A1 (enExample)
EA (1) EA201590237A1 (enExample)
IL (1) IL236714A0 (enExample)
MA (1) MA37961A1 (enExample)
MX (1) MX2015000730A (enExample)
NZ (1) NZ701974A (enExample)
SG (1) SG11201407841YA (enExample)
WO (1) WO2014013019A1 (enExample)
ZA (1) ZA201408938B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
CA3057758A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
US12103978B2 (en) * 2018-06-15 2024-10-01 Shanghai Miracogen Inc. Methods and materials for treating cancer
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
WO2020056338A1 (en) * 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
EP4190818A4 (en) * 2020-07-28 2024-08-07 Bio-Thera Solutions, Ltd. ANTI-HER2 ANTIBODY AND ITS USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CZ308720B6 (cs) * 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US7273608B2 (en) * 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
PT2073842E (pt) * 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
AU2010303415B2 (en) * 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Also Published As

Publication number Publication date
AU2013291964A1 (en) 2015-02-05
US20150166664A1 (en) 2015-06-18
CA2875486A1 (en) 2014-01-23
EP2874658A1 (en) 2015-05-27
NZ701974A (en) 2018-03-23
ZA201408938B (en) 2016-09-28
KR20150036710A (ko) 2015-04-07
MX2015000730A (es) 2015-08-06
BR112014032169A2 (pt) 2017-08-01
IL236714A0 (en) 2015-02-26
AU2013291964B2 (en) 2017-12-14
JP2015528802A (ja) 2015-10-01
EA201590237A1 (ru) 2015-05-29
SG11201407841YA (en) 2015-02-27
WO2014013019A1 (en) 2014-01-23
CN104394887A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
MA52742B1 (fr) Anticorps bispécifiques dll3-cd3
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CO2017005845A2 (es) Anticuerpos monoclonales aislados contra cd73
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
EA201590987A1 (ru) Соединения и способы их применения
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA201590997A1 (ru) Соединения и способы их применения
EA201590783A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MA40713A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
EP4425179A3 (en) Compositions and methods for enhanced fluorescence
MA43466A1 (fr) Traitements du cancer de l'utérus
MA53069A1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX2019006188A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
NZ710929A (en) Antibody drug conjugates
EA201591977A1 (ru) Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
EP4406612A3 (en) Anti-cd70 antibody drug conjugates
MA37975A1 (fr) Inhibiteurs de synthase de glucosylcéramide
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
WO2015009726A3 (en) Medical uses of cd38 agonists
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.